Modified intention to treat reporting in randomised controlled trials: Systematic review

BMJ (Online)

Volumn 340, Issue 7762, 2010, Pages 33-

  Abraha, Iosief ^a   Montedori, Alessandro ^a  

^a Regional Health Authority of Umbria   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYSIS; ARTICLE; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICAL LITERATURE; METHODOLOGY; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; SYSTEMATIC REVIEW; INFORMATION PROCESSING; RANDOMIZED CONTROLLED TRIAL (TOPIC);

DATA COLLECTION; INTENTION TO TREAT ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77956068940     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c2697     Document Type: Article

References (43)

1. Newell DJ. Intention-to-treat analysis: implications for quantitative and qualitative research. Int J Epidemiol 1992;21:837-41.
2. Lewis JA, Machin D. Intention to treat - who should use ITT? Br J Cancer 1993;68:647-50.
3. Tierney JF, Stewart LA. Investigating patient exclusion bias in meta-analysis. Int J Epidemiol 2005;34:79-87.
4. Nuesch E, Trelle S, Reichenbach S, Rutjes AW, Burgi E, Scherer M, et al. The effects of excluding patients from the analysis in randomised controlled trials: meta-epidemiological study. BMJ 2009;339:b3244.
5. Higgins J, Green S. Intention-to-treat issues. In: Cochrane Collaboration. Cochrane handbook for systematic reviews on interventions. Cochrane Collaboration, 2008.
6. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670-4. (Pubitemid 29423954)
7. Ruiz-Canela M, Martinez-Gonzalez MA, de Irala-Estevez J. Intention to treat analysis is related to methodological quality. BMJ 2000;320:1007.
8. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis: who is in? Who is out? J Fam Pract 2002;51:969-71.
9. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94.
10. Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials 2007;4:350-6.
11. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.N Engl J Med 1999;340:764-71.
12. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56. (Pubitemid 37430625)
13. Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med 2004;141:781-8. (Pubitemid 39524916)
14. Solomkin JS, Wilson SE, Christou NV, Rotstein OD, Dellinger EP, Bennion RS, et al. Results of a clinical trial of clinafloxacin versus imipenem/cilastatin for intraabdominal infections. Ann Surg 2001;233:79-87. (Pubitemid 32043607)
15. Chong G, Bhatnagar A, Cunningham D, Cosgriff TM, Harper PG, Steward W, et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Ann Oncol 2006;17:437-42. (Pubitemid 43329580)
16. Young JM, Feldman RA, Auerbach SM, Kaufman JM, Garcia CS, Shen W, et al. Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in menwith erectile dysfunction: US trial. J Androl 2005;26:310-8. (Pubitemid 40628966)
17. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL Study: a randomized controlled trial. JAMA 2001;285:1711-8. (Pubitemid 32259905)
18. Farnier M, Freeman MW, Macdonell G, Perevozskaya I, Davies MJ, Mitchel YB, et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 2005;26:897-905. (Pubitemid 40676570)
19. Raine TR, Harper CC, Rocca CH, Fischer R, Padian N, Klausner JD, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA 2005;293:54-62. (Pubitemid 40066699)
20. Altman DG. Missing outcomes in randomized trials: addressing the dilemma. Open Med 2009;3:e51-3.
21. Wood AM, White IR, Thompson SG. Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals. Clin Trials 2004;1:368-76.
22. Altman DG, Bland JM. Missing data. BMJ 2007;334:424.
23. Molenberghs G, Thijs H, Jansen I, Beunckens C, Kenward MG, Mallinckrodt C, et al. Analyzing incomplete longitudinal clinical trial data. Biostatistics 2004;5:445-64. (Pubitemid 41180218)
24. Fergusson D, Aaron SD, Guyatt G, Hebert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002;325:652-4.
25. D'Agostino RB Sr, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Stat Med 2003;22:169-86.
26. Gotzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006;295:1172-4.
27. Sheng D, Kim MY. The effects of non-compliance on intent-to-treat analysis of equivalence trials. Stat Med 2006;25:1183-99.
28. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.N Engl J Med 2004;351:1391-402.
29. Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol 2005;23:3343-51.
30. Greenspan SMD, Field-Munves EMD, Tonino RMD, Smith MBS, Petruschke RP, Wang LP, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2002;77:1044-52.
31. Berek JS, Taylor PT, Gordon A, Cunningham MJ, Finkler N, Orr J Jr, et al. Randomized, placebo-controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. J Clin Oncol 2004;22:3507-16. (Pubitemid 41103657)
32. Chene G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, et al. Intention-to-treat vs on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 trial group. Control Clin Trials 1998;19:233-48.
33. European Coronary Surgery Study Group. Coronary-artery bypass surgery in stable angina pectoris: survival at two years. Lancet 1979;1:889-93.
34. Porta N, Bonet C, Cobo E. Discordance between reported intention to- treat and per protocol analyses. J Clin Epidemiol 2007;60:663-9. (Pubitemid 46891765)
35. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i) ased medicine - selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003;326:1171-3.
36. Gotzsche PC. Believability of relative risks and odds ratios in abstracts: cross sectional study. BMJ 2006;333:231-4.
37. Chan AW, Altman DG. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 2005;330:753.
38. Chan AW, Hrobjartsson A, Haahr MT, Gotzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65. (Pubitemid 38669189)
39. Chan AW, Krleza-Jeric K, Schmid I, Altman DG.Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 2004;171:735-40. (Pubitemid 39319090)
40. Chan AW, Hrobjartsson A, Jorgensen KJ, Gotzsche PC, Altman DG. Discrepancies in sample size calculations and data analyses reported in randomised trials: comparison of publications with protocols. BMJ 2008;337:a2299.
41. Chan AW, Altman DG. Epidemiology and reporting of randomised trials published in PubMed journals. Lancet 2005;365:1159-62.
42. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285:1992-5.
43. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. Med J Aust 2006;185:263-7. (Pubitemid 44382877)